Anavex Life Sciences Corp.宣布其药物Anavex®3-71用于治疗精神分裂症的2期临床研究取得积极的顶线结果。该公司表示,这一研究成果为该药物的进一步开发提供了重要的临床数据支持。
Anavex Life Sciences Corp.宣布其药物Anavex®3-71用于治疗精神分裂症的2期临床研究取得积极的顶线结果。该公司表示,这一研究成果为该药物的进一步开发提供了重要的临床数据支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.